Nexstim Plc half-yearly report 1 January – 30 June 2018 (Unaudited)
Helsinki, Finland: 16 August 2018 - Highlights, January-June 2018
- Nexstim delivered its first Navigated Brain Therapy (NBT®) system in the US for the treatment of Major Depressive Disorder (MDD) following Nexstim's successful launch of the SmartFocusTM TMS technology at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting in New York in May 2018.
- Completed enrolment in a supplementary 60 patient Phase III E-FIT trial that is ongoing in the US for use of the NBT® system in rehabilitation of upper limb mobility following stroke. Trial results are expected within three weeks from publishing this H1 2018 report.
- Cash balance of € 10.3 million at end of June 2018, including new equity financing of € 1 million via a directed issue of new shares to Capricorn Health-tech Fund and EUR 4 million loan drawn from Kreos Capital V (UK) Limited.
- Revenues amounted to € 1.1 million (2017: € 1.1 million).
More info on Nexstim's website.
Next > Diagenode announces acquisition of Service Provider NXT-Dx to complement Epigenetics Assay Services
Previous > NGDATA accepted into G-Cloud 10 Framework